PAVmed
PAVM
23 hedge funds and large institutions have $3.12M invested in PAVmed in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 39 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
0.29% more ownership
Funds ownership: 0.02% → 0.31% (+0.29%)
15% less capital invested
Capital invested by funds: $3.67M → $3.12M (-$552K)
62% less funds holding
Funds holding: 60 → 23 (-37)
92% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 39
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$524K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$192K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$88.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$23.3K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$14.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
-$44.1K |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$41.5K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$40.6K |
| 4 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
-$36.8K |
| 5 |
Lido Advisors
Los Angeles,
California
|
-$35.4K |
PAVM Hedge Fund Activity: Q4 2023 in Review
23 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q4 2023, worth a combined $3.12M — down 15% from $3.67M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of PAVM and 3 opened new positions — a net loss of 36 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was First Manhattan, adding an estimated $524K. The largest seller was Levin Capital Strategies, exiting entirely with an estimated $44.1K sold.
- 23 institutional investors held PAVmed (PAVM) as of Q4 2023, down from 60 in Q3 2023.
- Funds reported $3.12M of PAVmed stock for Q4 2023, down 15% quarter-over-quarter.
- 3 funds opened new PAVmed positions in Q4 2023 and 39 closed out, a net change of -36 holders.
- The largest PAVmed buyer in Q4 2023 was First Manhattan, an estimated $524K added.
- The largest PAVmed seller in Q4 2023 was Levin Capital Strategies, an estimated $44.1K sold.
Based on aggregated 13F filings for Q4 2023.